Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis

OBJECTIVE: To assess the efficacy, safety, pharmacokinetics and pharmacodynamics of the anti-interleukin (IL)-1α/β dual variable domain immunoglobulin lutikizumab (ABT-981) in erosive hand osteoarthritis (HOA). METHODS: Patients with ≥1 erosive and ≥3 tender and/or swollen hand joints were randomise...

Descripción completa

Detalles Bibliográficos
Autores principales: Kloppenburg, Margreet, Peterfy, Charles, Haugen, Ida K, Kroon, Féline, Chen, Su, Wang, Li, Liu, Wei, Levy, Gwen, Fleischmann, Roy M, Berenbaum, Francis, van der Heijde, Désirée, Bansal, Prashant, Wittoek, Ruth, Feng, Sheng, Fang, Yuni, Saltarelli, Mary, Medema, Jeroen K, Levesque, Marc C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Osteoarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390132/
https://www.ncbi.nlm.nih.gov/pubmed/30552176
http://dx.doi.org/10.1136/annrheumdis-2018-213336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390132/
https://www.ncbi.nlm.nih.gov/pubmed/30552176
http://dx.doi.org/10.1136/annrheumdis-2018-213336

Ejemplares similares